Differentiated mu-opioid receptor pre-development candidates for the treatment of pain, plus backup molecules. Based on in vitro and in vivo profiles, our assets are expected to be differentiated therapeutics for the treatment of pain with diminished on-target adverse effects. See Article 1 below as well as our posters in the Publication tab.
We are also excited to initiate in Q32019 two hit-to-lead discovery programs. The targets are Sphingosine 1-phosphate receptor (S1P1) for the treatment of pain and Motilin receptor (MLNR) for gastroparesis disorders. See Articles 2, 3, and 4 below).
Other targets in consideration are GPCRs involved in neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular disease, metabolic disorders, pruritus, and immuno-onocology. Considering greater than 30% of currently marketed drugs target GPCRs we believe there are great opportunities for Mebias Discovery to play a crucial role in the development of new drugs devoid of on target side effects.
Superior to Standard of Care
Clear bias SAR established with strong G-protein agonism
in vivo data show greater therapeutic index due to diminished adverse effects resulting from bias agonism